Cochrane · systematic review · CD015017
Ivermectin for preventing and treating COVID‐19
Popp, M, Reis, S, Schießer, S, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
14
No studies
2
Included studies
NR
No studies 2 · 12.5%Ungraded 0 · 0%Very low 3 · 18.8%Low 8 · 50%Moderate 1 · 6.3%High 2 · 12.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsSummary of findings table 1
Population: people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated people with moderate disease (WHO scale 4 or 5) only
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at day 28 | RR 0.6 [0.14, 2.51] | 3 studies · 230 participants | Very low Downgraded: risk of bias, imprecision |
Worsening of clinical status: participants with new need for invasive mechanical ventilation or death at day 28 | RR 0.82 [0.33, 2.04] | 2 studies · 118 participants | Very low Downgraded: risk of bias, imprecision |
Improvement of clinical status: participants discharged alive at day 28 | RR 1.03 [0.78, 1.35] | 1 study · 73 participants | Low Downgraded: risk of bias, imprecision |
QoL at longest | no estimate extracted | NR | No studies |
Serious adverse events during the trial period | RR 1.55 [0.07, 35.89] | 2 studies · 197 participants | Very low Downgraded: risk of bias, imprecision |
Any adverse events during the trial period | RR 1.04 [0.61, 1.79] | 3 studies · 228 participants | Low Downgraded: risk of bias, imprecision |
Viral clearance at day 7 | RR 1.12 [0.8, 1.58] | 3 studies · 231 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings table 2
Population: all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at day 28 | RR 0.77 [0.47, 1.25] | 6 studies · 2860 participants | Moderate Downgraded: imprecision |
Worsening of clinical status: admission to hospital or death within 28 days | RR 1.09 [0.2, 6.02] | 2 studies · 590 participants | Low Downgraded: inconsistency |
Improvement of clinical status: all initial symptoms resolved (asymptomatic) at day 14 | RR 0.9 [0.6, 1.36] | 2 studies · 478 participants | Low Downgraded: risk of bias, inconsistency |
Improvement of clinical status: time to symptom resolution | no estimate extracted | NR | No studies |
QoL (physical component) at up to 28 days, measured on the PROMIS Global‐10 scale and normalized to values from 16.2, low QoL, to 67.2, maximum QoL | MD 0 | 1 study · 1358 participants | High |
QoL (mental component) at up to 28 days, measured on the PROMIS Global‐10 scale and normalized to values from 21.2, low QoL, to 67.6, maximum QoL | MD 0 | 1 study · 1358 participants | High |
Serious adverse events during the trial period | RR 2.27 [0.62, 8.31] | 5 studies · 1502 participants | Low Downgraded: risk of bias, imprecision |
Any adverse events during the trial period | RR 1.24 [0.87, 1.76] | 5 studies · 1502 participants | Low Downgraded: risk of bias, inconsistency |
Viral clearance at day 7 | RR 1.01 [0.69, 1.48] | 2 studies · 331 participants | Low Downgraded: risk of bias, imprecision |